To Evaluate the Efficacy and Safety of High-Dose Almonertinib Versus Osimertinib in the Second-Line Treatment of Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: a Multicenter, Randomized Controlled, Double-Blind Clinical Trial
Latest Information Update: 06 Jun 2024
At a glance
- Drugs Aumolertinib (Primary) ; Osimertinib
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ATTACK
- 05 May 2021 New trial record